MHRA-100183-PIP01-21-M01 (update)

Key Facts

Active Substance
Active Substance:
  • AZILSARTAN MEDOXOMIL
Invented Name
  • Edarbi
  • Edarbi
PIP Number MHRA-100183-PIP01-21-M01 (update)
Pharmaceutical form(s)
  • Tablet
  • Granules for oral suspension
Therapeutic area
Therapeutic area:
  • Cardiovascular Diseases
Conditions / Indications
Conditions / Indications:
  • Treatment of hypertension
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):AZILSARTAN MEDOXOMIL.pdf
Published Date 29/07/2022